Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Church & Dwight Set to Meet Q3 Outlook, Potentially Lift Guidance, Oppenheimer Says

Church & Dwight Set to Meet Q3 Outlook, Potentially Lift Guidance, Oppenheimer Says

MT newswireMT newswire2026/10/28 16:18
12:18 PM EDT, 10/28/2026 (MT Newswires) -- Church & Dwight (CHD) is expected to deliver strong Q3 quarterly results and potentially raise guidance, Oppenheimer said in a note Wednesday. The company is scheduled to report the results on Oct. 30. The analysts said they expect the company to at least meet Q3 management guidance for about 3% organic sales growth and earnings per share of $0.89, supported by steady demand, product innovation, and strong brands such as Hero and TheraBreath. Management could raise the lower end of its 2026 guidance range, however, it may reinvest some of its upside into the business, limiting the size of any outlook increase, the analysts added. "In all, we view the setup as a bit less attractive into the print and would take advantage of any profit taking that materializes," the analysts said, adding that they remain positive on the company's long-term prospects. Oppenheimer raised its price target on Church & Dwight to $120 from $115 and kept its outperform rating. Price: 104.75, Change: -0.26, Percent Change: -0.25
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

CoreWeave (CRWV.US) bonds hit a new low as changes in Texas data center policies impact AI cloud trading

CoreWeave (CRWV.US) bonds fell sharply on Wednesday, with some dropping to new lows.

智通财经•2026/11/05 01:51
CoreWeave (CRWV.US) bonds hit a new low as changes in Texas data center policies impact AI cloud trading

AstraZeneca (AZN.US) reportedly receives a $10 billion acquisition offer! Shares of obesity drug developer Rhythm (RYTM.US) soar in response

According to three people familiar with the matter, AstraZeneca previously proposed to acquire obesity drug developer Rhythm Pharmaceuticals for approximately 10 billion dollars.

智通财经•2026/11/05 01:36

Goldman Sachs and Apollo in Talks to Sell 40 Billion-Dollar AI Chip Financing for SpaceX (SPCX.US), Market's Willingness to Take Over Faces Test

Goldman Sachs (GS.US) and Apollo Global Management (APO.US) are in talks with Wall Street investors to begin selling portions of a roughly $40 billion chip financing deal for SpaceX (SPCX.US).

智通财经•2026/11/05 01:07
Goldman Sachs and Apollo in Talks to Sell 40 Billion-Dollar AI Chip Financing for SpaceX (SPCX.US), Market's Willingness to Take Over Faces Test